# US 2025/0154102 A1 · Cyclic lipids and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154102 A1
- Document ID: US20250154102A1
- Status: Published application
- Kind: A1
- Application number: 18/906,526
- Filed: 2024-10-04
- Published: 2025-05-15
- Earliest claimed: 2022-04-07
- Assignees: ReNAgade Therapeutics Management Inc.
- Applicants: ReNAgade Therapeutics Management Inc.
- Inventors: Muthusamy Jayaraman; Stephen Scully
- Web page: https://patentgrep.com/patent/US20250154102A1

## CPC

- C07D 211/40: Oxygen atoms
- C07D 211/42: attached in position 3 or 5
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/24: Oxygen or sulfur atoms
- C07D 211/20: with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 223/08: Oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

## Claims

### Claim 1

A compound of Formula (CX-II)
or a pharmaceutically acceptable salt thereof,
wherein
Z is selected from the group consisting of a bond,
each Y is independently selected from the group consisting of
R1 is —(CH2)1-6N(Ra)2 or —(CH2)1-6OH;
R2 is optionally substituted C5-C36 alkyl or optionally substituted C5-C36 alkenyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2, and wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
R2′ is optionally substituted C1-C36 alkyl or optionally substituted C5-C36 alkenyl, wherein 1-6 methylene units of R2′ are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
each Ra is independently optionally substituted C1-C6 alkyl; or
two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
m is 0, 1, or 2;
n is 1 or 2; and
p is 1 or 2.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is represented by formula (CX-II-a):
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is represented Formula (CX-II-b), (CX-II-c), or (CX-II-d)
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is represented by formula (CX-II-e):
or a pharmaceutically acceptable salt thereof.

### Claim at position 6

7-8. (canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 1-3 methylene units of R2′ are optionally replaced with —O—.

### Claim 10 (depends on 1)

The compound of claim 1, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2′ are replaced with —O— to form an acetal within R2′.

### Claim 11 (depends on 1)

The compound of claim 1, wherein
R2 is optionally substituted C10-C24 alkyl or optionally substituted C10-C24 alkenyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2 and wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—; and
R2′ is optionally substituted C10-C24 alkenyl, wherein 1-3 methylene units of R2′ are optionally replaced with —O—.

### Claim at position 10

12-54. (canceled)

### Claim 55

A compound of table (II) or a pharmaceutically acceptable salt thereof.

### Claim 56 (depends on 1)

A lipid nanoparticle (LNP) comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 13

57-78. (canceled)

### Claim 79 (depends on 55)

A lipid nanoparticle (LNP) comprising a compound of claim 55, or a pharmaceutically acceptable salt thereof.

### Claim 80

A compound of Formula (CZ-I)
or a pharmaceutically acceptable salt thereof,
wherein
Z is selected from the group consisting of a bond,
each Y is independently selected from the group consisting of,
R1 is —(CH2)1-6N(Ra)2;
each R2 is independently optionally substituted C1-C36 alkyl or optionally substituted C2-C36 alkenyl, wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
each Ra is independently optionally substituted C1-C6 alkyl; or
two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
m is 0, 1, or 2;
n is 1 or 2; and
p is 1 or 2.

### Claim 81 (depends on 80)

The compound of claim 80, wherein the compound is represented by Formula (CZ-I-a), (CZ-I-b), (CZ-I-c), or (CZ-I-d)
or a pharmaceutically acceptable salt thereof.

### Claim 82 (depends on 80)

The compound of claim 80, wherein the compound is represented by Formula (CZ-I-e) or (CZ-I-f)
or a pharmaceutically acceptable salt thereof.

### Claim 83 (depends on 80)

The compound of claim 80, wherein the compound is represented by Formula (CZ-I-g)
or a pharmaceutically acceptable salt thereof.

### Claim 84 (depends on 80)

The compound of claim 80, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 1-3 methylene units of R2′ are optionally replaced with —O—.

### Claim 85 (depends on 80)

The compound of claim 80, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2′ are replaced with —O— to form an acetal within R2′.

### Claim 86 (depends on 80)

A lipid nanoparticle (LNP) comprising a compound of claim 80, or a pharmaceutically acceptable salt thereof.

### Claim 87

A compound of Formula (CZ-II)
or a pharmaceutically acceptable salt thereof,
wherein
Z is selected from the group consisting of a bond,
each Y is independently selected from the group consisting of,
R1 is —(CH2)1-6N(Ra)2;
each R2 is independently optionally substituted C1-C36 alkyl or optionally substituted C2-C36 alkenyl, wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
each Ra is independently optionally substituted C1-C6 alkyl; or
two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
m is 0, 1, or 2;
n is 1 or 2; and
p is 1 or 2.

### Claim 88 (depends on 87)

The compound of claim 87, wherein the compound is represented by Formula (CZ-II-a), (CZ-II-b), (CZ-II-c), or (CZ-II-d)
or a pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 87)

The compound of claim 87, wherein the compound is represented by Formula (CZ-II-e)
or a pharmaceutically acceptable salt thereof.

### Claim 90 (depends on 87)

The compound of claim 87, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 1-3 methylene units of R2′ are optionally replaced with —O—.

### Claim 91 (depends on 87)

The compound of claim 87, wherein
R2 is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2; and
R2′ is optionally substituted C10-C24 alkyl, wherein 2 methylene units of R2′ are replaced with —O— to form an acetal within R2′.

### Claim 92 (depends on 87)

A lipid nanoparticle (LNP) comprising a compound of claim 87, or a pharmaceutically acceptable salt thereof.
